APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Tumor Necrosis Factor Receptor Superfamily Member 1A

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Tumor Necrosis Factor Receptor Superfamily Member 1A Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174043740326 December 2025185 pages

Choose your research edition.

Industry ResearchTumor Necrosis Factor Receptor Superfamily Member 1A Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Tumor Necrosis Factor Receptor Superfamily Member 1A Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Tumor Necrosis Factor Receptor Superfamily Member 1A Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tumor Necrosis Factor Receptor Superfamily Member 1A Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Tumor Necrosis Factor Receptor Superfamily Member 1A Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Tumor Necrosis Factor Receptor Superfamily Member 1A market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Tumor Necrosis Factor Receptor Superfamily Member 1A is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Tumor Necrosis Factor Receptor Superfamily Member 1A is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tumor Necrosis Factor Receptor Superfamily Member 1A is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Tumor Necrosis Factor Receptor Superfamily Member 1A is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Tumor Necrosis Factor Receptor Superfamily Member 1A include Addex Therapeutics Ltd, G&E Herbal Biotechnology Co., Ltd., Inflamalps SA, Polaris Pharmaceuticals, Inc. and GlaxoSmithKline Plc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Tumor Necrosis Factor Receptor Superfamily Member 1A market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Tumor Necrosis Factor Receptor Superfamily Member 1A and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Tumor Necrosis Factor Receptor Superfamily Member 1A sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Tumor Necrosis Factor Receptor Superfamily Member 1A market size, projected growth trends, production technologies, key applications, and end-use industries.

Tumor Necrosis Factor Receptor Superfamily Member 1A Segment by Company

Addex Therapeutics Ltd

G&E Herbal Biotechnology Co., Ltd.

Inflamalps SA

Polaris Pharmaceuticals, Inc.

GlaxoSmithKline Plc

Tumor Necrosis Factor Receptor Superfamily Member 1A Segment by Type

EYS-606

LY-3232094

SRT-100

Others

Tumor Necrosis Factor Receptor Superfamily Member 1A Segment by Application

Multiple Sclerosis

Melanoma

Genital Warts

Psoriasis

Others

Tumor Necrosis Factor Receptor Superfamily Member 1A Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Necrosis Factor Receptor Superfamily Member 1A market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tumor Necrosis Factor Receptor Superfamily Member 1A and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Necrosis Factor Receptor Superfamily Member 1A.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Tumor Necrosis Factor Receptor Superfamily Member 1A market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Tumor Necrosis Factor Receptor Superfamily Member 1A manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Tumor Necrosis Factor Receptor Superfamily Member 1A in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Tumor Necrosis Factor Receptor Superfamily Member 1A in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Tumor Necrosis Factor Receptor Superfamily Member 1A Industry Trends Table 2. Tumor Necrosis Factor Receptor Superfamily Member 1A Industry Drivers Table 3. Tumor Necrosis Factor Receptor Superfamily Member 1A Industry Opportunities and Challenges Table 4. Tumor Necrosis Factor Receptor Superfamily Member 1A Industry Restraints Table 5. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Manufacturers Table 9. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Manufacturers, Product Type & Application Table 13. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Tumor Necrosis Factor Receptor Superfamily Member 1A by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of EYS-606 Table 17. Major Manufacturers of LY-3232094 Table 18. Major Manufacturers of SRT-100 Table 19. Major Manufacturers of Others Table 20. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 21. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Type (2021-2026) & (W Units) Table 22. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Type (2027-2032) & (W Units) Table 23. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Type (2021-2026) Table 24. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Type (2027-2032) Table 25. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 26. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Type (2021-2026) & (W Units) Table 27. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Type (2027-2032) & (W Units) Table 28. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Type (2021-2026) Table 29. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Multiple Sclerosis Table 31. Major Manufacturers of Melanoma Table 32. Major Manufacturers of Genital Warts Table 33. Major Manufacturers of Psoriasis Table 34. Major Manufacturers of Others Table 35. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 36. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Application (2021-2026) & (W Units) Table 37. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Application (2027-2032) & (W Units) Table 38. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Application (2021-2026) Table 39. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Application (2027-2032) Table 40. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 41. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Application (2021-2026) & (W Units) Table 42. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Application (2027-2032) & (W Units) Table 43. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Application (2021-2026) Table 44. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Application (2027-2032) Table 45. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 46. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Region (2021-2026) & (W Units) Table 47. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Region (2021-2026) Table 48. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Forecasted by Region (2027-2032) & (W Units) Table 49. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 51. North America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Country (2021-2026) & (W Units) Table 52. North America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Country (2027-2032) & (W Units) Table 53. Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 54. Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Country (2021-2026) & (W Units) Table 55. Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Country (2027-2032) & (W Units) Table 56. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 57. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Country (2021-2026) & (W Units) Table 58. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Country (2027-2032) & (W Units) Table 59. South America, Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 60. South America, Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Country (2021-2026) & (W Units) Table 61. South America, Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Country (2027-2032) & (W Units) Table 62. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Region (2021-2026) Table 66. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Region (2027-2032) Table 67. Addex Therapeutics Ltd Company Information Table 68. Addex Therapeutics Ltd Business Overview Table 69. Addex Therapeutics Ltd Tumor Necrosis Factor Receptor Superfamily Member 1A Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Addex Therapeutics Ltd Tumor Necrosis Factor Receptor Superfamily Member 1A Product Portfolio Table 71. Addex Therapeutics Ltd Recent Development Table 72. G&E Herbal Biotechnology Co., Ltd. Company Information Table 73. G&E Herbal Biotechnology Co., Ltd. Business Overview Table 74. G&E Herbal Biotechnology Co., Ltd. Tumor Necrosis Factor Receptor Superfamily Member 1A Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. G&E Herbal Biotechnology Co., Ltd. Tumor Necrosis Factor Receptor Superfamily Member 1A Product Portfolio Table 76. G&E Herbal Biotechnology Co., Ltd. Recent Development Table 77. Inflamalps SA Company Information Table 78. Inflamalps SA Business Overview Table 79. Inflamalps SA Tumor Necrosis Factor Receptor Superfamily Member 1A Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Inflamalps SA Tumor Necrosis Factor Receptor Superfamily Member 1A Product Portfolio Table 81. Inflamalps SA Recent Development Table 82. Polaris Pharmaceuticals, Inc. Company Information Table 83. Polaris Pharmaceuticals, Inc. Business Overview Table 84. Polaris Pharmaceuticals, Inc. Tumor Necrosis Factor Receptor Superfamily Member 1A Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Polaris Pharmaceuticals, Inc. Tumor Necrosis Factor Receptor Superfamily Member 1A Product Portfolio Table 86. Polaris Pharmaceuticals, Inc. Recent Development Table 87. GlaxoSmithKline Plc Company Information Table 88. GlaxoSmithKline Plc Business Overview Table 89. GlaxoSmithKline Plc Tumor Necrosis Factor Receptor Superfamily Member 1A Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. GlaxoSmithKline Plc Tumor Necrosis Factor Receptor Superfamily Member 1A Product Portfolio Table 91. GlaxoSmithKline Plc Recent Development Table 92. Key Raw Materials Table 93. Raw Materials Key Suppliers Table 94. Tumor Necrosis Factor Receptor Superfamily Member 1A Distributors List Table 95. Tumor Necrosis Factor Receptor Superfamily Member 1A Customers List Table 96. Research Programs/Design for This Report Table 97. Authors List of This Report Table 98. Secondary Sources Table 99. Primary Sources List of Figures Figure 1. Tumor Necrosis Factor Receptor Superfamily Member 1A Product Image Figure 2. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size (2021-2032) & (US$ Million) Figure 4. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales (2021-2032) & (W Units) Figure 5. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Tumor Necrosis Factor Receptor Superfamily Member 1A Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. EYS-606 Image Figure 9. LY-3232094 Image Figure 10. SRT-100 Image Figure 11. Others Image Figure 12. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 13. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Type (2021-2032) Figure 15. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 16. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Type (2021-2032) Figure 18. Multiple Sclerosis Image Figure 19. Melanoma Image Figure 20. Genital Warts Image Figure 21. Psoriasis Image Figure 22. Others Image Figure 23. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 24. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Application (2021-2032) Figure 26. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 27. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Application (2021-2032) Figure 29. North America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales and Growth Rate (2021-2032) & (W Units) Figure 30. North America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Country (2021-2032) Figure 31. U.S. Tumor Necrosis Factor Receptor Superfamily Member 1A Sales and Growth Rate (2021-2032) & (W Units) Figure 32. Canada Tumor Necrosis Factor Receptor Superfamily Member 1A Sales and Growth Rate (2021-2032) & (W Units) Figure 33. Mexico Tumor Necrosis Factor Receptor Superfamily Member 1A Sales and Growth Rate (2021-2032) & (W Units) Figure 34. Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Sales and Growth Rate (2021-2032) & (W Units) Figure 35. Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Country (2021-2032) Figure 36. Germany Tumor Necrosis Factor Receptor Superfamily Member 1A Sales and Growth Rate (2021-2032) & (W Units) Figure 37. France Tumor Necrosis Factor Receptor Superfamily Member 1A Sales and Growth Rate (2021-2032) & (W Units) Figure 38. U.K. Tumor Necrosis Factor Receptor Superfamily Member 1A Sales and Growth Rate (2021-2032) & (W Units) Figure 39. Italy Tumor Necrosis Factor Receptor Superfamily Member 1A Sales and Growth Rate (2021-2032) & (W Units) Figure 40. Netherlands Tumor Necrosis Factor Receptor Superfamily Member 1A Sales and Growth Rate (2021-2032) & (W Units) Figure 41. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Sales and Growth Rate (2021-2032) & (W Units) Figure 42. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Country (2021-2032) Figure 43. China Tumor Necrosis Factor Receptor Superfamily Member 1A Sales and Growth Rate (2021-2032) & (W Units) Figure 44. Japan Tumor Necrosis Factor Receptor Superfamily Member 1A Sales and Growth Rate (2021-2032) & (W Units) Figure 45. South Korea Tumor Necrosis Factor Receptor Superfamily Member 1A Sales and Growth Rate (2021-2032) & (W Units) Figure 46. Southeast Asia Tumor Necrosis Factor Receptor Superfamily Member 1A Sales and Growth Rate (2021-2032) & (W Units) Figure 47. India Tumor Necrosis Factor Receptor Superfamily Member 1A Sales and Growth Rate (2021-2032) & (W Units) Figure 48. Australia Tumor Necrosis Factor Receptor Superfamily Member 1A Sales and Growth Rate (2021-2032) & (W Units) Figure 49. South America, Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Sales and Growth Rate (2021-2032) & (W Units) Figure 50. South America, Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Country (2021-2032) Figure 51. Brazil Tumor Necrosis Factor Receptor Superfamily Member 1A Sales and Growth Rate (2021-2032) & (W Units) Figure 52. South Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Sales and Growth Rate (2021-2032) & (W Units) Figure 53. Saudi Arabia Tumor Necrosis Factor Receptor Superfamily Member 1A Sales and Growth Rate (2021-2032) & (W Units) Figure 54. Turkey Tumor Necrosis Factor Receptor Superfamily Member 1A Sales and Growth Rate (2021-2032) & (W Units) Figure 55. Argentina Tumor Necrosis Factor Receptor Superfamily Member 1A Sales and Growth Rate (2021-2032) & (W Units) Figure 56. UAE Tumor Necrosis Factor Receptor Superfamily Member 1A Sales and Growth Rate (2021-2032) & (W Units) Figure 57. Egypt Tumor Necrosis Factor Receptor Superfamily Member 1A Sales and Growth Rate (2021-2032) & (W Units) Figure 58. Chile Tumor Necrosis Factor Receptor Superfamily Member 1A Sales and Growth Rate (2021-2032) & (W Units) Figure 59. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2021-2032) & (US$ Million) Figure 62. North America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2021-2032) & (US$ Million) Figure 64. Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Tumor Necrosis Factor Receptor Superfamily Member 1A Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Tumor Necrosis Factor Receptor Superfamily Member 1A Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • EYS-606
  • LY-3232094
  • SRT-100
  • Others
Applications
  • Multiple Sclerosis
  • Melanoma
  • Genital Warts
  • Psoriasis
  • Others
Companies covered
  • Addex Therapeutics Ltd
  • G&E Herbal Biotechnology Co., Ltd.
  • Inflamalps SA
  • Polaris Pharmaceuticals, Inc.
  • GlaxoSmithKline Plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Market Dynamics
  1. 2.1 Tumor Necrosis Factor Receptor Superfamily Member 1A Industry Trends
  2. 2.2 Tumor Necrosis Factor Receptor Superfamily Member 1A Industry Drivers
  3. 2.3 Tumor Necrosis Factor Receptor Superfamily Member 1A Industry Opportunities and Challenges
  4. 2.4 Tumor Necrosis Factor Receptor Superfamily Member 1A Industry Restraints
3 Tumor Necrosis Factor Receptor Superfamily Member 1A Market by Manufacturers
  1. 3.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Manufacturers (2021-2026)
  3. 3.3 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Manufacturers, Product Type & Application
  7. 3.7 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Tumor Necrosis Factor Receptor Superfamily Member 1A Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Tumor Necrosis Factor Receptor Superfamily Member 1A Tier 1, Tier 2, and Tier 3
4 Tumor Necrosis Factor Receptor Superfamily Member 1A Market by Type
  1. 4.1 Tumor Necrosis Factor Receptor Superfamily Member 1A Type Introduction
  2. 4.1.1 EYS-606
  3. 4.1.2 LY-3232094
  4. 4.1.3 SRT-100
  5. 4.1.4 Others
  6. 4.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Type
  7. 4.2.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Type (2021-2032)
  9. 4.2.3 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Type (2021-2032)
  10. 4.3 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Type
  11. 4.3.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Type (2021-2032)
  13. 4.3.3 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Type (2021-2032)
5 Tumor Necrosis Factor Receptor Superfamily Member 1A Market by Application
  1. 5.1 Tumor Necrosis Factor Receptor Superfamily Member 1A Application Introduction
  2. 5.1.1 Multiple Sclerosis
  3. 5.1.2 Melanoma
  4. 5.1.3 Genital Warts
  5. 5.1.4 Psoriasis
  6. 5.1.5 Others
  7. 5.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Application
  8. 5.2.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Application (2021-2032)
  10. 5.2.3 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Application (2021-2032)
  11. 5.3 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Application
  12. 5.3.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Application (2021-2032)
  14. 5.3.3 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Application (2021-2032)
6 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Region
  1. 6.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Region (2021-2032)
  3. 6.2.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Region (2021-2026)
  4. 6.2.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Region
  1. 7.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Region
  2. 7.1.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Region (2021-2026)
  4. 7.1.3 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Region (2027-2032)
  5. 7.1.4 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2021-2032)
  8. 7.2.2 North America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2021-2032)
  11. 7.3.2 Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Addex Therapeutics Ltd
  2. 8.1.1 Addex Therapeutics Ltd Company Information
  3. 8.1.2 Addex Therapeutics Ltd Business Overview
  4. 8.1.3 Addex Therapeutics Ltd Tumor Necrosis Factor Receptor Superfamily Member 1A Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Addex Therapeutics Ltd Tumor Necrosis Factor Receptor Superfamily Member 1A Product Portfolio
  6. 8.1.5 Addex Therapeutics Ltd Recent Developments
  7. 8.2 G&E Herbal Biotechnology Co., Ltd.
  8. 8.2.1 G&E Herbal Biotechnology Co., Ltd. Company Information
  9. 8.2.2 G&E Herbal Biotechnology Co., Ltd. Business Overview
  10. 8.2.3 G&E Herbal Biotechnology Co., Ltd. Tumor Necrosis Factor Receptor Superfamily Member 1A Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 G&E Herbal Biotechnology Co., Ltd. Tumor Necrosis Factor Receptor Superfamily Member 1A Product Portfolio
  12. 8.2.5 G&E Herbal Biotechnology Co., Ltd. Recent Developments
  13. 8.3 Inflamalps SA
  14. 8.3.1 Inflamalps SA Company Information
  15. 8.3.2 Inflamalps SA Business Overview
  16. 8.3.3 Inflamalps SA Tumor Necrosis Factor Receptor Superfamily Member 1A Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Inflamalps SA Tumor Necrosis Factor Receptor Superfamily Member 1A Product Portfolio
  18. 8.3.5 Inflamalps SA Recent Developments
  19. 8.4 Polaris Pharmaceuticals, Inc.
  20. 8.4.1 Polaris Pharmaceuticals, Inc. Company Information
  21. 8.4.2 Polaris Pharmaceuticals, Inc. Business Overview
  22. 8.4.3 Polaris Pharmaceuticals, Inc. Tumor Necrosis Factor Receptor Superfamily Member 1A Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Polaris Pharmaceuticals, Inc. Tumor Necrosis Factor Receptor Superfamily Member 1A Product Portfolio
  24. 8.4.5 Polaris Pharmaceuticals, Inc. Recent Developments
  25. 8.5 GlaxoSmithKline Plc
  26. 8.5.1 GlaxoSmithKline Plc Company Information
  27. 8.5.2 GlaxoSmithKline Plc Business Overview
  28. 8.5.3 GlaxoSmithKline Plc Tumor Necrosis Factor Receptor Superfamily Member 1A Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline Plc Tumor Necrosis Factor Receptor Superfamily Member 1A Product Portfolio
  30. 8.5.5 GlaxoSmithKline Plc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Tumor Necrosis Factor Receptor Superfamily Member 1A Value Chain Analysis
  2. 9.1.1 Tumor Necrosis Factor Receptor Superfamily Member 1A Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Tumor Necrosis Factor Receptor Superfamily Member 1A Production Mode & Process
  6. 9.2 Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Tumor Necrosis Factor Receptor Superfamily Member 1A Distributors
  9. 9.2.3 Tumor Necrosis Factor Receptor Superfamily Member 1A Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst